# Week of January 30 – February 3, 2023

## OUHSC DEPARTMENT OF MEDICINE CONFERENCE SCHEDULE

**NOTE: All CME conferences will be designated by an \* by the name of the conference.**

|  |  |
| --- | --- |
| **Monday, January 30, 2023** |  |

 12:15 – 1:00 PM Medicine House Staff Conference: “Case Report,” Lauren Roton, Medicine/Pediatrics Resident. AAT Conf Rm A&B

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: “Diagnosis and Management of Malignant Pleural Effusions,” Shalini Mehta, Assistant Professor, Department of Medicine/Pulmonary. AAT 8200

 2:00 – 3:00 PM Geriatric Medicine Fellowship: TBA/Speaker. Zoom Meeting <https://zoom.us/j/93015900472?pwd=YUpoa2pIUGk5VFRicmNMSFJHZitEQT09>

|  |  |
| --- | --- |
| **Tuesday, January 31, 2023** |  |

 7:15 – 8:00 AM Cardiology Cath Conference: Board Review/Didactic Session. AAT 5200 or Zoom Meeting

 8:00 – 9:00 AM Endocrinology Grand Rounds/Research Conference: TBA/Speaker. HHDC 2923

 Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to:

 12:15 – 1:15 PM **\***Medicine Grand Rounds: “(Meth)amphetamine and the Risk of Pulmonary Hypertension,” Roham T. Zamanian, MD, Associate Professor of Medicine, Director, Adult Pulmonary Hypertension Program, Associate Director, Vera Moulton Wall Center for Pulmonary Vascular Disease, Division of Pulmonary & Critical Care Medicine, Stanford University School of Medicine. Available by Zoom Meeting ID: 915 6165 6346 Passcode: 90357946 <https://zoom.us/j/91561656346?pwd=bmoxQVU0TTZCSjlSbTdXYUY3MFV0QT09> or join us by phone, 1-602-753-0140 (1.00 *AMA PRA Category 1 Credit™)*

Professional Practice Gap: Gap 1: How to diagnose and treat methamphetamine PAH. Gap 2: What are the outcomes of Meth-APAH

 Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to: Discuss the epidemiology of methamphetamine and prescription amphetamines in the modern era. Discuss the association between (meth) amphetamines and pulmonary vascular disease. Evaluate the clinical approach and treatment of Methamphetamine associated PAH.

|  |  |
| --- | --- |
| **Wednesday, February 1, 2023** |  |

 7:00 – 8:00 AM Vascular Conference: AAT 9200

 7:15 – 8:00 AM Cardiology Program Director Meeting: AAT 5200

 8:00 – 9:00 AM Geriatric Journal Club: Zoom Meeting

 <https://zoom.us/j/98058292229?pwd=ejRsYzdlNGIrNkZjTytiMVUyd2NzUT09>

 8:15 – 9:00 AM ID Case Conference: AAT Conf Rm C

 12:15 – 1:00 PM Medicine House Staff Conference: “Case Report,” Ahmad Basil Nasir, MD, Medicine/Pediatrics Resident. AAT Conf Rm A&B

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: “Interprofessional Team Work – How to Professionally Interact with Consultants, Faculty, Fellows and Residents,” Brent Brown, MD, Professor, Department of Medicine/Pulmonary. AAT 8200

**Department of Medicine Conference Schedule January 30 – February 3, 2023**

|  |  |
| --- | --- |
| **Wednesday, February 1, 2023 Continued** |  |

 1:30 – 2:30 PM Renal Grand Rounds: Case Consultation: AAT 5328

 1:30 – 3:30 PM Rheumatology Clinical Conference: “Dermatology,” Jarad Levin, MD, Assistant Professor, Department of Dermatology. Zoom Meeting

 3:00 – 4:00 PM GI SOCI & Interdisciplinary Reports Conference: “Committee Reports on QI &/OR Patient Safety Projects and Adverse Events,” Maham Hayat, MD, Digestive Diseases Fellow, Justin Kosirog, MD, Digestive Diseases Fellow and Hashroop Gurm, MD, Digestive Diseases Fellow. AAT Conf Rm, 1st Fl, Rm C

 4:00 – 5:00 PM GI Advanced Endoscopy Conference: AAT Conf Rm, 1st Fl, Rm C

|  |  |
| --- | --- |
|  **Thursday, February 2, 2023** |  |

 7:15 – 8:00 AM Cardiovascular Grand Rounds: TBA/Speaker. Zoom Meeting

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: Journal Club. AAT 8200

|  |  |
| --- | --- |
| **Friday, February 3, 2023** |  |

 7:15 – 8:00 AM Echocardiography Conference: AAT 5200

 8:00 – 9:00 AM Hematology/Oncology Grand Rounds Conference: “TBA,” Leah Rosenberg, MD, Assistant Professor, Department of Medicine, Harvard Medical School, . SCC 6039/Zoom Meeting

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: Instructive Case Conference. AAT 8200

 1:30 – 2:30 PM Combined Thoracic-Oncology Clinical Care Conference: VAMC 5F-121

For accommodations on the basis of disability, call 405-271-6655 x1.

FUTURE EVENTS

To place name on mailing list or provide input for future schedules, contact Ms. Brenda Wilkerson, Department of Medicine. Schedules are typically e-mailed on Thursday of the week prior to the week of listed activities. If you wish to receive this via e-mail, you may use the Internet to request it. Address: Brenda-Wilkerson@ouhsc.edu

**Accreditation Statement:** The University Of Oklahoma College Of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

**Acknowledgement of Commercial and In-Kind Support:** Commercial support is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity received no commercial or in-kind support.

**University of Oklahoma Equal Opportunity/Non-Discrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at [link.ou.edu/reportingform](file:///%5C%5Cdch-comd1%5Cdo%5Cocpd%5C22D%20RSS%202021-2022%5C22D%20To%20Do%5Clink.ou.edu%5Creportingform).

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit [www.ou.edu/eoo](http://www.ou.edu/eoo).

**Accommodations Statement:** For accommodations, please contact the Dept. of Medicine at 405-271-6651 ext. 1.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  |  |  |
| --- | --- | --- |
| **Role**  | **First Name** | **Last Name**  | **Commercial Interest** | **Nature of the Financial Relationship** |
| Planning Committee/ Presenter | Adam S. | Asch, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee/ Presenter | Mary Zoe | Baker, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Course Director/ Moderator | Michael S.  | Bronze, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee/ Presenter/ Moderator | Benjamin D. | Cowley, Jr, MD | Otsuka | Consultant Fee  |
| **Planner:** Dr. Cowley has recused himself from planning content in the conflicted area. **Moderator:** Dr. Cowley will limit his role to the introduction of presenters, fielding questions, and moderating the flow of discussion between participants and presenters. **Presenter:** The conflict was resolved by Dr. Cowley agreeing to only present peer-reviewed, published data and recommendations that have been previewed by the OU CPD office. |
| Planning Committee / Presenter / Moderator | Douglas A. | Drevets, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee | Courtney W. | Houchen, MD | COARE Biotechnology | Grants/Research  |
| **Planner:** Dr. Houchen has recused himself from planning content in the conflicted area. |
| Planning Committee / Presenter | Mary Beth | Humphrey, MD, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee | Rhett L. | Jackson, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee / Presenter | Matlock | Jefferies, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee | Lee A. | Jennings, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee / Presenter | Stephen | Pilkington, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee / Presenter | Dwight W. | Reynolds, MD | Medtronic, Inc | Honorarium  |
| Medtronic, Inc | Research FundingPrimary Investigator |
| **Planner:** Dr. Reynolds has recused himself from planning content in the conflicted areas. **Presenter:** The conflict was resolved by Dr. Reynolds agreeing that the presentation(s) will not include discussion of any products or services from the commercial interests. |
| Course Contact | Brenda E. | Wilkerson | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee / Presenter | Houssein | Youness, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Presenter | Roham | Zamanian, MD | Janssen Biotech | Consulting Fee |
| Vivus | Advisor |
| Morphogenix | Consulting Fee |
| United Therapeutics | Grant/Research Support |
| Genentech USA | Stocks or stock options, excluding diversified mutual funds |
| GossamerBio | Membership on Advisory Committees or Review Panels, Board Membership, etc |
| The conflict was mitigated by Dr. Zamanian agreeing that the presentation will not include discussion of any products or services from any of the ineligible companies with which financial relationships exist.This presentation will be evaluated by participants for fair balance. |